Innoskel
Valbonne
About Innoskel
InnoSkel is a pioneering platform biotechnology company developing therapies for rare skeletal diseases. InnoSkel is developing treatment options for a group of rare skeletal disorders collectively known as type 2 collagenopathies, the most severe of which is Spondyloepiphyseal Dysplasia congenita (SEDc), the second leading cause of dwarfism worldwide. InnoSkel’s lead gene therapy asset for SEDc has demonstrated good efficacy in proof-of-concept studies. The company’s fundamental mission is to improve the lives of patients living with skeletal dysplasia and to answer their unmet needs, keeping their voices at the heart of all they do. InnoSkel is a spin-out of the Institut de Biology Valrose at Inserm, the French National Institute of Health and Medical Research, and is based in Nice, France.
Company Facts
- Operating status: Closed
- Company type: For Profit
- IPO status: Private
- Employees: 1 – 10
- Estimated revenue: $1K – $10K
- Total funding: $24.3M
- Funding stage: Early Stage Venture
- Last round: Series A (Dec 2020)
- Website: innoskel.com
- Phone: +44 (0) 20 3709 5700
Industries & Categories
Biotechnology, Therapeutics
Social Profiles
Canonical: https://fsome.com/organization/innoskel-154422 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.